Low within-and between-day variability in exposure to new insulin glargine 300 U/ml

被引：0

作者：

Becker, R. H. ^{[1
]}

Nowotny, I. ^{[1
]}

Teichert, L. ^{[1
]}

Bergmann, K. ^{[1
]}

Kapitza, C. ^{[2
]}

机构：

[1] Sanofi Aventis Deutschland GmbH, Frankfurt, Germany

[2] Profil, Neuss, Germany

来源：

DIABETOLOGIA | 2014年 / 57卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

953

引用

页码：S390 / S390

页数：1

共 50 条

[31] Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important? [J].

Bonadonna, Riccardo C. ;

Renard, Eric ;

Cheng, Alice ;

Fritsche, Andreas ;

Cali, Anna ;

Melas-Melt, Lydie ;

Umpierrez, Guillermo E. .

DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 142 :19-25

[32] PREDICTION OF HYPOGLYCEMIA IN PATIENTS TREATED WITH INSULIN GLARGINE 300 U/ML FOR BASAL INSULIN THERAPY [J].

Takeishi, S. ;

Inoue, T. .

DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 :A176-A177

[33] Insulin glargine 300 U/ml versus Insulin degludec 100 U/ml Direct Comparison of long-acting Insulins [J].

Stiefelhagen, Peter .

AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 2019, 12 (01) :38-38

[34] COMPARISON OF INSULIN GLARGINE 300 U/ML, INSULIN DEGLUDEC AND INSULIN GLARGINE 100 U/ML, IN BASAL INSULIN THERAPY USING FREESTYLE LIBRE PRO: RANDOMISED TRIPLE CROSSOVER STUDY [J].

Takeishi, S. ;

Tsuboi, H. ;

Takekoshi, S. .

DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 :A137-A137

[35] An Exploratory Study to Evaluate the Glycemic Variability by Continuous Glucose Monitoring (CGM) with Insulin Glargine 300 U/mL vs. Glargine 100 U/mL in Patients with Type 2 Diabetes [J].

Franco, Denise R. ;

Visconti, Guilherme D. ;

Feder, Cecilia ;

Baptista, Juliana ;

Vianna, Andre G. ;

Guimaraes, Mariana T. ;

Souza, Flavia V. ;

Tagata, Luciana A. ;

Eliaschewitz, Freddy .

DIABETES, 2020, 69

[36] New insulin glargine 300U/ml (Gla-300): glycaemic control and hypoglycaemia in insulin-naive people with Type 2 diabetes compared with glargine 100U/ml (Gla-100) [J].

Bolli, G. B. ;

Riddle, M. C. ;

Bergenstal, R. M. ;

Sestakauskas, K. ;

Goyeau, H. ;

Home, P. D. .

DIABETIC MEDICINE, 2015, 32 :78-78

[37] Insulin Glargine 300 U/mL Therapy in Children and Adolescents with Type 1 Diabetes [J].

Maffeis, Claudio ;

Rabbone, Ivana .

PEDIATRIC DRUGS, 2022, 24 (05) :499-512

[38] INSULIN GLARGINE 300U/ML AND INSULIN GLARGINE 100U/ML SHOW EQUIPOTENT IN VIVO BLOOD GLUCOSE LOWERING WHEN ADMINISTERED INTRAVENOUSLY IN DOGS [J].

Werner, U. ;

Korn, M. ;

Tennagels, N. .

DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 :A119-A119

[39] Insulin Glargine 300 U/mL Therapy in Children and Adolescents with Type 1 Diabetes [J].

Claudio Maffeis ;

Ivana Rabbone .

Pediatric Drugs, 2022, 24 :499-512

[40] Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance [J].

Owens, David R. .

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (08) :977-987

← 1 2 3 4 5 →